SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(van Beek Stijn W.)
 

Sökning: WFRF:(van Beek Stijn W.) > (2023) > Drug interaction po...

  • Stemkens, RalfRadboud Univ Nijmegen, Med Ctr, Dept Pharm, Nijmegen, Netherlands. (författare)

Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis

  • Artikel/kapitelEngelska2023

Förlag, utgivningsår, omfång ...

  • American Society for Microbiology,2023
  • electronicrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:uu-522989
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-522989URI
  • https://doi.org/10.1128/aac.00683-23DOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Accumulating evidence supports the use of higher doses of rifampicin for tuberculosis (TB) treatment. Rifampicin is a potent inducer of metabolic enzymes and drug transporters, resulting in clinically relevant drug interactions. To assess the drug interaction potential of higher doses of rifampicin, we compared the effect of high-dose rifampicin (40 mg/kg daily, RIF40) and standard-dose rifampicin (10 mg/kg daily, RIF10) on the activities of major cytochrome P450 (CYP) enzymes and P-glycoprotein (P-gp). In this open-label, single-arm, two-period, fixed-order phenotyping cocktail study, adult participants with pulmonary TB received RIF10 (days 1–15), followed by RIF40 (days 16–30). A single dose of selective substrates (probe drugs) was administered orally on days 15 and 30: caffeine (CYP1A2), tolbutamide (CYP2C9), omeprazole (CYP2C19), dextromethorphan (CYP2D6), midazolam (CYP3A), and digoxin (P-gp). Intensive pharmacokinetic blood sampling was performed over 24 hours after probe drug intake. In all, 25 participants completed the study. Geometric mean ratios (90% confidence interval) of the total exposure (area under the concentration versus time curve, RIF40 versus RIF10) for each of the probe drugs were as follows: caffeine, 105% (96%–115%); tolbutamide, 80% (74%–86%); omeprazole, 55% (47%–65%); dextromethorphan, 77% (68%–86%); midazolam, 62% (49%–78%), and 117% (105%–130%) for digoxin. In summary, high-dose rifampicin resulted in no additional effect on CYP1A2, mild additional induction of CYP2C9, CYP2C19, CYP2D6, and CYP3A, and marginal inhibition of P-gp. Existing recommendations on managing drug interactions with rifampicin can remain unchanged for the majority of co-administered drugs when using high-dose rifampicin. Clinical Trials registration number NCT04525235.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • de Jager, VeroniqueTASK, Cape Town, South Africa. (författare)
  • Dawson, RodneyUniv Cape Town, Div Pulmonol, Cape Town, South Africa.;Univ Cape Town, Dept Med, Cape Town, South Africa.;Univ Cape Town, Lung Inst, Cape Town, South Africa. (författare)
  • Diacon, Andreas H.TASK, Cape Town, South Africa. (författare)
  • Narunsky, KimUniv Cape Town, Div Pulmonol, Cape Town, South Africa.;Univ Cape Town, Dept Med, Cape Town, South Africa.;Univ Cape Town, Lung Inst, Cape Town, South Africa. (författare)
  • Padayachee, Sherman D.Univ Cape Town, Div Pulmonol, Cape Town, South Africa.;Univ Cape Town, Dept Med, Cape Town, South Africa.;Univ Cape Town, Lung Inst, Cape Town, South Africa. (författare)
  • Boeree, Martin J.Radboud Univ Nijmegen, Med Ctr, Dept Pulm Dis, Nijmegen, Netherlands. (författare)
  • van Beek, Stijn W.Radboud Univ Nijmegen, Med Ctr, Dept Pharm, Nijmegen, Netherlands (författare)
  • Colbers, AngelaRadboud Univ Nijmegen, Med Ctr, Dept Pharm, Nijmegen, Netherlands. (författare)
  • Coenen, Marieke J. H.Erasmus Univ, Med Ctr, Rotterdam, Netherlands. (författare)
  • Svensson, Elin M.,1985-Uppsala universitet,Institutionen för farmaci,Radboud Univ Nijmegen, Med Ctr, Dept Pharm, Nijmegen, Netherlands(Swepub:uu)elisv718 (författare)
  • Fuhr, UweUniv Cologne, Fac Med, Ctr Pharmacol, Clin Pharmacol,Dept Pharmacol 1, Cologne, Germany.;Univ Cologne, Univ Hosp Cologne, Cologne, Germany. (författare)
  • Phillips, Patrick P. J.Univ Calif San Francisco, UCSF Ctr TB, San Francisco, CA USA. (författare)
  • te Brake, Lindsey H. M.Radboud Univ Nijmegen, Med Ctr, Dept Pharm, Nijmegen, Netherlands. (författare)
  • Aarnoutse, Rob E.Radboud Univ Nijmegen, Med Ctr, Dept Pharm, Nijmegen, Netherlands. (författare)
  • Radboud Univ Nijmegen, Med Ctr, Dept Pharm, Nijmegen, Netherlands.TASK, Cape Town, South Africa. (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Antimicrobial Agents and Chemotherapy: American Society for Microbiology67:100066-48041098-6596

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy